OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the tre
OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Okyo Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on Nasdaq at $1.54 per share.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.